Literature DB >> 8880388

New drug development for pediatric oncology.

S Weitman1, L Carlson, C B Pratt.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8880388     DOI： 10.1007/bf00173677

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  68 in total

Review 1.  Clinical trials in pediatric oncology.

Authors:  B G Leventhal; M L Graham
Journal:  Semin Oncol       Date:  1988-10       Impact factor: 4.929

2.  Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion.

Authors:  J M Koeller; D L Trump; K D Tutsch; R H Earhart; T E Davis; D C Tormey
Journal:  Cancer       Date:  1986-01-15       Impact factor: 6.860

3.  Phase I. evaluation of cyclocytidine (NSC-145668).

Authors:  J J Lokich; P L Chawla; N Jaffe; E Frei
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

4.  Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans.

Authors:  J S Kovach; M M Ames; G Powis; C G Moertel; R G Hahn; E T Creagan
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

5.  Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

Authors:  L Saltz; M Sirott; C Young; W Tong; D Niedzwiecki; Y Tzy-Jyun; Y Tao; B Trochanowski; P Wright; K Barbosa
Journal:  J Natl Cancer Inst       Date:  1993-09-15       Impact factor: 13.506

6.  Phase I study of carboplatin (CBDCA) in children with cancer.

Authors:  D M Bacha; B Caparros-Sison; J A Allen; R Walker; C T Tan
Journal:  Cancer Treat Rep       Date:  1986-07

7.  Therapeutic response in phase I trials of antineoplastic agents.

Authors:  E Estey; D Hoth; R Simon; S Marsoni; B Leyland-Jones; R Wittes
Journal:  Cancer Treat Rep       Date:  1986-09

8.  Phase I study of indicine N-oxide in patients with advanced cancer.

Authors:  T Ohnuma; K S Sridhar; L H Ratner; J F Holland
Journal:  Cancer Treat Rep       Date:  1982-07

9.  Phase I clinical evaluation of diaziquone in childhood cancer.

Authors:  L J Ettinger; S E Siegel; J B Belasco; A E Evans; K S Ruccione; D C Jamin; T M Rohrbaugh; G R Higgins
Journal:  Cancer Treat Rep       Date:  1985-03

10.  Phase I study of oral etoposide in children with refractory solid tumors.

Authors:  P Mathew; R C Ribeiro; D Sonnichsen; M Relling; C Pratt; H Mahmoud; L Bowman; W Meyer; L Avery; W Crist
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.